Board of Directors
The Board of Directors at IBEX is comprised of a knowledgeable team of talented individuals with a wealth of experience in the pharmaceutical industry.
Chairman, President and CEO.
Previously, Executive Vice-President, Sterling Winthrop Pharmaceuticals, New York, NY; Senior Vice President, CIBA-GEIGY Pharmaceuticals, Summit, NJ.; President CIBA-GEIGY Pharmaceuticals, Montreal QC.
Bruce Connop, Ph.D.
Director, Member of the Audit and Governance Committees.
Currently Vice President, Non-Clinical & Pharmaceutical Development, Transition Therapeutics. Dr. Connop received a doctorate in Pharmacology & Toxicology from Queen’s University, Kingston, Ontario, followed by a Post-Doctoral Fellowship at the University of British Columbia.
Robert J. DeLuccia, MBA
Director, Chair of the Governance Committee and Member of the Audit Committee.
Currently Managing Partner and Co-Founder ACURX Pharmaceuticals. Previously, Executive Chairman, Dipexium Pharmaceuticals, New York, NY; Executive Chairman, Macrochem Corporation, Lexington, MA; Chief Executive Officer, Immunomedics, Morris Plains, NJ; President, Sanofi Winthrop (now Sanofi), New York, NY.
Danilo Netto, CMA
Director, Chairman of the Audit Committee and Member of the Governance Committee.
Currently Chief Financial Officer, Avior Integrated Products Inc. Previously, Vice President Finance and Chief Financial Officer, IBEX Technologies Inc.; National Director of Finance, Business Development, Nestle Canada.
Joseph Zimmerman, Ph.D.
Director and Chair of the Compensation Committee.
Currently President, CEO and Founder of Biodextris Inc., Laval, Previously: Director, New Product Development GSK Vaccines, Laval, Quebec., Director, Process Development & Project Leader, FluINsure ID Biomedical, Montreal, Quebec. Dr. Zimmermann received a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology, a Masters of Philosophy in Pharmacology from Cambridge University (UK) and a Bachelor of Science in Chemical Engineering from Columbia University.